The Relationship Of Glycemic Exposure (HbA1c) To The Risk ... - PubMed

Clipboard, Search History, and several other advanced features are temporarily unavailable. Skip to main page content

The .gov means it’s official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation Search: Search Advanced Clipboard Save Email Send to

• Clipboard
• My Bibliography
• Collections
• Citation manager

Display options Display options Format Abstract PubMed PMID

Save citation to file

Format: Summary (text) PubMed PMID Abstract (text) CSV Create file Cancel

Email citation

Email address has not been verified. Go to My NCBI account settings to confirm your email and then refresh this page. To: Subject: Body: Format: Summary Summary (text) Abstract Abstract (text) MeSH and other data Send email Cancel

Add to Collections

• Create a new collection
• Add to an existing collection

Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error Please try again Add Cancel

Add to My Bibliography

• My Bibliography

Unable to load your delegates due to an error Please try again Add Cancel

Your saved search

Name of saved search: Search terms: Test search terms Would you like email updates of new search results? Saved Search Alert Radio Buttons

• Yes
• No

Email: (change) Frequency: Monthly Weekly Daily Which day? The first Sunday The first Monday The first Tuesday The first Wednesday The first Thursday The first Friday The first Saturday The first day The first weekday Which day? Sunday Monday Tuesday Wednesday Thursday Friday Saturday Report format: Summary Summary (text) Abstract Abstract (text) PubMed Send at most: 1 item 5 items 10 items 20 items 50 items 100 items 200 items Send even when there aren't any new results Optional text in email: Save Cancel

Create a file for external citation management software

Create file Cancel

Your RSS Feed

Name of RSS Feed: Number of items displayed: 5 10 15 20 50 100 Create RSS Cancel RSS Link Copy

Actions

CiteCollectionsAdd to Collections

• Create a new collection
• Add to an existing collection

Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an errorPlease try again Add Cancel PermalinkPermalinkCopyDisplay options Display options Format AbstractPubMedPMID

Page navigation

• Title & authors
• Abstract
• Publication types
• MeSH terms
• Substances
• LinkOut - more resources

Title & authors Abstract Publication types MeSH terms Substances LinkOut - more resources CiteDisplay options Display options Format AbstractPubMedPMID

Abstract

The Diabetes Control and Complications Trial (DCCT) demonstrated that a regimen of intensive therapy aimed at maintaining near-normal blood glucose values markedly reduces the risks of development or progression of retinopathy and other complications of insulin-dependent diabetes mellitus (IDDM) when compared with a conventional treatment regimen. This report presents an epidemiological assessment of the association between levels of glycemic exposure (HbA1c) before and during the DCCT with the risk of retinopathy progression within each treatment group. The initial level of HbA1c observed at eligibility screening as an index of pre-DCCT glycemia and the duration of IDDM on entry were the dominant baseline predictors of the risk of progression. The shorter the duration of IDDM on entry, the greater were the benefits of intensive therapy. In each treatment group, the mean HbA1c during the trial was the dominant predictor of retinopathy progression, and the risk gradients were similar in the two groups; a 10% lower HbA1c (e.g., 8 vs. 7.2%) is associated with a 43% lower risk in the intensive group and a 45% lower risk in the conventional group. These risk gradients applied over the observed range of HbA1c values and were unaffected by adjustment for other covariates. Over the range of HbA1c achieved by DCCT intensive therapy, there does not appear to be a level of glycemia below which the risks of retinopathy progression are eliminated. The change in risk over time, however, differed significantly between the treatment groups, the risk increasing with time in the study in the conventional group but remaining relatively constant in the intensive group. The risks were compounded by a multiplicative effect of the level of HbA1c with the duration of exposure (time in study). Total glycemic exposure was the dominant factor associated with the risk of retinopathy progression. When examined simultaneously within each treatment group, each of the components of pre-DCCT glycemic exposure (screening HbA1c value and IDDM duration) and glycemic exposure during the DCCT (mean HbA1c, time in study, and their interaction) were significantly associated with risk of retinopathy progression. Similar results also apply to other retinopathic, nephropathic, and neuropathic outcomes. The recommendation of the DCCT remains that intensive therapy with the goal of achieving near-normal glycemia should be implemented as early as possible in as many IDDM patients as is safely possible.

PubMed Disclaimer

Publication types

• Clinical Trial Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Comparative Study Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Controlled Clinical Trial Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Multicenter Study Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Research Support, U.S. Gov't, P.H.S. Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search

MeSH terms

• Biomarkers / blood Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Blood Glucose / metabolism Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Cohort Studies Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Demography Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Diabetes Mellitus, Type 1 / blood Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Diabetes Mellitus, Type 1 / drug therapy Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Diabetes Mellitus, Type 1 / physiopathology* Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Diabetic Angiopathies / epidemiology Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Diabetic Angiopathies / physiopathology Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Diabetic Nephropathies / epidemiology Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Diabetic Nephropathies / physiopathology Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Diabetic Neuropathies / epidemiology Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Diabetic Neuropathies / physiopathology Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Diabetic Retinopathy / epidemiology* Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Diabetic Retinopathy / physiopathology* Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Diabetic Retinopathy / prevention & control Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Energy Intake Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Female Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Follow-Up Studies Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Glycated Hemoglobin / metabolism* Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Humans Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Male Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Primary Prevention Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Regression Analysis Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Risk Factors Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Time Factors Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search

Substances

• Biomarkers Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Blood Glucose Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Glycated Hemoglobin A Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • ClinicalTrials.gov
  • MedlinePlus Health Information

[x] Cite Copy Download .nbib .nbib Format: AMA APA MLA NLM Send To

• Clipboard
• Email
• Save
• My Bibliography
• Collections
• Citation Manager

[x]

NCBI Literature Resources

MeSH PMC Bookshelf Disclaimer

The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.